Yüklüyor......
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has form...
Kaydedildi:
| Yayımlandı: | Expert Rev Anticancer Ther |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Informa Healthcare
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4673554/ https://ncbi.nlm.nih.gov/pubmed/26313416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2015.1081566 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|